傳染病檢測市場－全球產業規模、佔有率、趨勢、機會和預測（按產品與服務、按技術、按疾病、按最終用戶、按地區和競爭細分，2020-2030 年）

2024 年全球傳染病檢測市場價值為 340.9 億美元，預計在預測期內將呈現令人印象深刻的成長，到 2030 年的複合年成長率為 7.71%。細菌、寄生蟲、病毒和真菌是傳染病的病原體。這些疾病的識別和表徵屬於傳染病診斷領域。醫生和醫療保健專業人員主要依靠患者的症狀和身體檢查來檢測傳染病。他們會進行一系列實驗室測試來確定病原體，使醫療保健提供者能夠實施適當的醫療治療。病原體可以透過直接接觸、水或食物傳播、環境中受感染顆粒的氣溶膠化以及透過昆蟲（如蚊子）和蜱蟲傳播。

免疫系統受損的人特別容易受到某些感染。這包括正在接受癌症治療或近期接受器官移植的人。未接種常見傳染病疫苗的人、醫護人員以及前往瘧疾和登革熱等蚊媒病原體高風險地區的人員面臨更高的風險。醫生會使用各種實驗室檢查來診斷傳染病。全球傳染病檢測市場在及時診斷和管理各種傳染病方面發揮關鍵作用。隨著病毒和細菌感染的日益流行，整個醫療保健系統對快速、準確且易於獲取的診斷工具的需求也日益增加。市場包括針對愛滋病毒、肝炎、結核病、流感等疾病以及最近出現的新冠病毒和猴痘等威脅的檢測解決方案。

技術進步是關鍵驅動力，尤其是分子診斷、即時檢測和實驗室自動化的應用。這些創新縮短了周轉時間，提高了敏感度和特異性，並改善了疾病監測。家庭護理和遠距診所等分散式醫療保健場所的擴張進一步刺激了對攜帶式和易用型檢測試劑盒的需求。例如，2024年12月，摩洛哥生物技術公司Moldiag推出了非洲首款本地生產的mpox檢測試劑盒，這是加強非洲大陸醫療保健自給自足能力的重要里程碑。這項進展減少了對進口診斷工具的依賴，並增強了區域應對傳染病疫情的能力。 Moldiag的舉措標誌著非洲在建立生物技術基礎設施和改善及時獲取基本診斷解決方案方面取得了關鍵進展。

關鍵市場促進因素

傳染病日益流行

主要市場挑戰

報銷不足

主要市場趨勢

即時檢驗 (POCT)

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球傳染病檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品和服務（分析、試劑盒、試劑、儀器、服務和軟體）
  • 按技術（分子診斷、免疫測定、微生物學、其他）
  • 依疾病（肝炎、人類乳突病毒 (HPV)、人類免疫缺乏病毒(HIV)、結核病 (TB)、醫院內感染 (HAI)、其他）
  • 按最終使用者（醫院和臨床實驗室、診斷參考實驗室、學術/研究機構、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美傳染病檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲傳染病檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太傳染病檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲傳染病檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲傳染病檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第13章：全球傳染病檢測市場：SWOT分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

第 16 章：策略建議

第17章調查會社について,免責事項

Global Infectious Disease Testing Market has valued at USD 34.09 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.71% through 2030F. Bacteria, parasites, viruses, and fungi are the causative agents of infectious diseases. The identification and characterization of these diseases fall under the domain of infectious disease diagnostics. Physicians and healthcare professionals primarily rely on patients' symptoms and physical examinations to detect infectious infections. A range of laboratory tests is conducted to determine the causative agents, enabling healthcare providers to administer appropriate medical treatments. Pathogens can be transmitted through direct contact, water or foodborne routes, aerosolization of infected particles in the environment, as well as via insects (such as mosquitoes) and ticks.

Individuals with compromised immune systems are particularly vulnerable to certain infections. This includes those undergoing cancer treatment or recent organ transplant recipients. The individuals who have not been vaccinated against common infectious diseases, healthcare workers, and those traveling to high-risk areas with mosquito-borne pathogens like malaria and dengue fever are at increased risk. Various laboratory tests are employed by doctors to diagnose infectious disorders. The global infectious disease testing market plays a critical role in the timely diagnosis and management of a wide array of contagious illnesses. With the growing prevalence of both viral and bacterial infections, there is a heightened need for rapid, accurate, and accessible diagnostic tools across healthcare systems. The market includes testing solutions for diseases such as HIV, hepatitis, tuberculosis, influenza, and more recently, emerging threats like COVID-19 and monkeypox.

Technological advancements have been a key driver, particularly the adoption of molecular diagnostics, point-of-care testing, and automation in laboratories. These innovations enable quicker turnaround times, increased sensitivity and specificity, and improved disease surveillance. The expansion of decentralized healthcare settings, such as home care and remote clinics, has further spurred demand for portable and easy-to-use test kits. For instance, in December 2024, Moroccan biotech company Moldiag launched Africa's first locally produced mpox test kits, representing a major milestone in strengthening the continent's healthcare self-sufficiency. This development reduces dependence on imported diagnostic tools and enhances regional capacity to respond to infectious disease outbreaks. Moldiag's initiative marks a critical advancement in building Africa's biotechnology infrastructure and improving timely access to essential diagnostic solutions.

Key Market Drivers

Increasing Prevalence of Infectious Diseases

The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The rising prevalence of infectious diseases, particularly tuberculosis (TB), is a key driver of growth in the global infectious disease testing market. According to WHO, TB caused 1.25 million deaths in 2023, making it the world's leading infectious killer, surpassing COVID-19. With an estimated 10.8 million people falling ill globally, including many with drug-resistant TB, the demand for early, accurate, and accessible diagnostic testing continues to rise. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. The globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.

The aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.

The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.

Key Market Challenges

Inadequate Reimbursements

Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.

Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.

Key Market Trends

Point-of-Care Testing (POCT)

POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.

In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.

Key Market Players

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

Report Scope:

In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Testing Market, By Product & Service:

• Assays
• Kits
• Reagents
• Instruments
• Services & Software

Infectious Disease Testing Market, By Technology:

• Molecular Diagnostics
• Immunoassay
• Microbiology
• Others

Infectious Disease Testing Market, By Disease:

• Hepatitis
• Human Papillomavirus (HPV)
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Hospital-Acquired Infections (HAIs)
• Others

Infectious Disease Testing Market, By End User:

• Hospital and Clinical Laboratories
• Diagnostic Reference Laboratories
• Academic/Research Institutes
• Others

Infectious Disease Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.

Available Customizations:

Global Infectious Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Assays, Kits, Reagents, Instruments, Services & Software)
  • 5.2.2. By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others)
  • 5.2.3. By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others)
  • 5.2.4. By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Infectious Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Disease
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Infectious Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Infectious Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Infectious Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease
      • 6.3.3.2.4. By End User

7. Europe Infectious Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Disease
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Infectious Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Infectious Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Infectious Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease
      • 7.3.3.2.4. By End User
  • 7.3.4. France Infectious Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Infectious Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease
      • 7.3.5.2.4. By End User

8. Asia-Pacific Infectious Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Disease
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Infectious Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease
      • 8.3.1.2.4. By End User
  • 8.3.2. India Infectious Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Infectious Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Infectious Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Infectious Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease
      • 8.3.5.2.4. By End User

9. South America Infectious Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Disease
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Infectious Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Infectious Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Infectious Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease
      • 9.3.3.2.4. By End User

10. Middle East and Africa Infectious Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Disease
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Infectious Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Infectious Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Infectious Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Infectious Disease Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Biomerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. Danaher Corporation
• 15.6. F. Hoffmann-La Roche AG
• 15.7. Siemens Healthineers AG
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. Quidel Corporation
• 15.10. Trinity Biotech PLC

16. Strategic Recommendations

17. About Us & Disclaimer